Talha Badar/X
Jun 16, 2025, 04:16
Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Emergence of ASXL1 and tyrosine kinase domain mutation with different TKI; imatinib, 2nd generation TKI and asciminib. Best choice of TKI with respect to mutation.”
More posts featuring Talha Badar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 6, 2025, 07:47
Jul 6, 2025, 07:09
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52